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Abstract
The actin cytoskeleton is a primary determinant of tumor cell motility and metastatic potential. Motility and metastasis are
thought to be regulated, in large part, by the interaction of membrane proteins with cytoplasmic linker proteins and of
these linker proteins, in turn, with actin. However, complete membrane-to-actin linkages have been difficult to identify. We
used co-immunoprecipitation and competitive peptide assays to show that intercellular adhesion molecule-2 (ICAM-2)/a-
actinin/actin may comprise such a linkage in neuroblastoma cells. ICAM-2 expression limited the motility of these cells and
redistributed actin fibers in vitro, and suppressed development of disseminated tumors in an in vivo model of metastatic
neuroblastoma. Consistent with these observations, immunohistochemical analysis demonstrated ICAM-2 expression in
primary neuroblastoma tumors exhibiting features that are associated with limited metastatic disease and more favorable
clinical outcome. In neuroblastoma cell lines, ICAM-2 expression did not affect AKT activation, tumorigenic potential or
chemosensitivity, as has been reported for some types of transfected cells. The observed ICAM-2-mediated suppression of
metastatic phenotype is a novel function for this protein, and the interaction of ICAM-2/a-actinin/actin represents the first
complete membrane-linker protein-actin linkage to impact tumor cell motility in vitro and metastatic potential in an in vivo
model. Current work focuses on identifying specific protein domains critical to the regulation of neuroblastoma cell motility
and metastasis and on determining if these domains represent exploitable therapeutic targets.
Citation: Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, et al. (2008) ICAM-2 Expression Mediates a Membrane-Actin Link, Confers a Nonmetastatic
Phenotype and Reflects Favorable Tumor Stage or Histology in Neuroblastoma. PLoS ONE 3(11): e3629. doi:10.1371/journal.pone.0003629
Editor: Nils Cordes, Dresden University of Technology, Germany
Received May 6, 2008; Accepted October 13, 2008; Published November 3, 2008
Copyright:  2008 Yoon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by CA21765 and American Lebanese Syrian Associated Charities.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: karina.yoon@stjude.org
Introduction
The actin network is a primary determinant of the motility of
cells and organelles. This complex network regulates the
movement of amoebae, distribution of bacteria within cells, cell
migration in embryogenesis and angiogenesis, and the migratory
and invasive (metastatic) potential of tumor cells. In tumor cells,
motility and metastasis are thought to be regulated at least in part
by the interaction of membrane-bound proteins with the actin
cytoskeletal network [1–5]. Multiple signaling pathways and
protein interactions modulate the motility and migration of tumor
cells [3–8], but specific molecular interactions that control the
complicated process of metastasis have been difficult to identify. In
normal cells, the interaction of a particular membrane-bound cell
adhesion molecule with a specific cytoplasmic linker protein has
been associated with a unique cell function. In inactive
neutrophils, for example, membrane-bound b2-integrin binds to
the cytoplasmic linker protein talin. In contrast, in activated
neutrophils b2-integrin binds to an alternate linker protein, a-
actinin [9]. While both talin and a-actinin can bind directly to
actin, it is not yet known how the association of b2-integrin with
each linker proteins affects their binding to actin.
In tumor cells, members of the ezrin-radixin-moesin (ERM)
family of cytoplasmic actin cytoskeletal linker proteins play critical
roles in the regulation of metastatic potential. ERM linker proteins,
as well as a-actinin, merlin, and band 4.1 linker proteins [4–6,10–
12], have been implicated in tumor progression or in suppression of
the metastatic potential of tumor cells. Cell adhesion molecules
(CAMs) to which these linker proteins bind, such as deleted in colon
cancer (DCC) and carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1), are members of the IgG superfamily to
which ICAM-2 belongs. DCC and CEACAM1 contribute to the
adhesive, migratory, or invasive properties of several types of solid
tumor cells [13–16] including neuroblastoma [17], but the
molecular interactions that mediate these functions have been
difficult to identify. The data herein suggest that in neuroblastoma
cells the association of ICAM-2 with a-actinin and actin may
represent such an interaction.
Other functions have also been reported for ICAM-2.
Particularly well characterized are its roles as a co-stimulatory
signal for T cell stimulation [18] and in mediating neutrophil
adhesion and migration through endothelial cell monolayers [19–
21]. These roles have been documented by in vivo [22–24] as well
as in vitro methods. In specific cell types ICAM-2 also activates the
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3629PI3Kinase/AKT pathway [25,26] and promotes cell migration
[27], suggesting that this adhesion molecule has multiple,
apparently unrelated functions. Neither the expression nor the
function of ICAM-2 in neuroblastoma cells has been investigated
previously.
Neuroblastoma is a pediatric tumor thought to arise from cells
of the neural crest. Patients diagnosed with neuroblastoma
frequently achieve complete remissions, but up to 80% of high-
risk patients develop metastatic disease that does not respond to
therapy [28]. As is true for most types of solid tumors, the primary
cause of death is the development of metastatic disease; but no
current therapies specifically target the metastatic process, as a
potential approach for limiting the occurrence or the progression
of disseminated tumors. The integral role of cell motility
(migration and invasion) in the metastatic process and data in
the literature suggesting the potential involvement of CAMs in
regulating cell motility provided the rationale for the studies
reported here. The long-range goal of the work is to identify
molecular interactions that regulate the metastatic potential of
neuroblastoma, and to determine if these molecular interactions
represent potential therapeutic targets.
Results
ICAM-2 associates with a-actinin and actin to establish a
membrane-to-actin linkage
In tumor cells, proteins of the cytoplasmic actin linker families
contribute to tumorigenesis and metastasis. RT-PCR analysis of a
panel of neuroblastoma cell lines (data not shown) showed that
neuroblastoma cells express two of these linker proteins: ezrin and
a-actinin. Ezrin and a-actinin bind to the intracellular domain of
the intercellular adhesion molecule-2 (ICAM-2) [29,30] and to
actin. Therefore, we postulated that membrane-bound ICAM-2
binds to cytoplasmic ezrin or a-actinin which, in turn, binds to
actin to regulate the motility—and hence the metastatic
potential—of neuroblastoma cells.
We first demonstrated using immunoblotting, that 6 of 6
neuroblastoma cells express ICAM-2 (Fig. 1A). ICAM-2 protein
had the expected apparent mass of 55–60 kDa [31] in all six
neuroblastoma cell lines (as well as other types of solid tumor cell
lines [data not shown]), and the level of ICAM-2 expression varied
with SJNB-1A.NB-1691, SK-N-SH and NB-1643.SK-N-AS
and IMR-32.
We then transfected a cell line with low endogenous ICAM-2
expression (SK-N-AS) with control pIRESneo or with the ICAM-
2-encoding plasmid, and compared the phenotypes of the stable
congenic transfected cell lines. Immunoblots of whole cell lysates of
SK-N-ASpIRESneo and SK-N-ASpIRES.ICAM2 cells confirmed
that the transfectants expressed similar levels of actin, a-actinin,
and ezrin, but differed in levels of ICAM-2 expression (Fig. 1B). As
reported for normal endothelial cells [19], immunoperoxidase
staining of paraffin-embedded cells showed that ICAM-2 in
transfected SK-N-ASpIRES.ICAM2 cells localized to cell mem-
branes (Fig. 1C).
Using these transfectants, we conducted co-immunoprecipita-
tion assays to determine whether a-actinin or ezrin associated with
Figure 1. In neuroblastoma cells, membrane-bound ICAM-2 associates with a-actinin and actin. A) Immunoblot of whole cell lysates
(35 mg protein/lane) of six neuroblastoma cell lines, comparing endogenous levels of expression of ICAM-2. B) Immunoblots of SK-N-AS cells
transfected with control plasmid (pIRESneo) or with plasmid encoding ICAM-2 (pIRES.ICAM2) show that transfectants expressed similar levels of a-
actinin, ezrin, and actin, but SK-N-ASpIRES.ICAM2 cells expressed a higher level of ICAM-2 than SK-N-ASpIRESneo cells (25 mg protein/lane). C) ICAM-2
expressed in SK-N-ASpIRES.ICAM2 cells localized to cell membranes (examples indicated by red arrows). D) Co-immunoprecipitation co-precipitation/
mass spectroscopic analysis (actin) showed that actin co-precipitated with ICAM-2 in ICAM-2 transfectants. Band #1 was .99% identical to human
actin. E) Immunoprecipitation/immunoblot showing equal amounts of a-actinin precipitated from lysates of SK-N-ASpIRESneo and SK-N-
ASpIRES.ICAM2 cells. F) Immunoprecipitation/immunoblots showing that ICAM-2 and actin co-precipitated with a-actinin in lysates from SK-N-
ASpIRES.ICAM2 cells, but little if any ICAM-2 and actin co-precipitated with a-actinin in SK-N-ASpIRESneo cells.
doi:10.1371/journal.pone.0003629.g001
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in lysates from pIRESneo and pIRES.ICAM2 transfectants were
immunoprecipitated with a monoclonal antibody to ICAM-2, and
an aliquot of precipitated proteins was analyzed by immunoblot
with a polyclonal antiserum to this protein. The blot in the lower
panel of Fig. 1D shows the expected difference in level of ICAM-2
precipitated from ICAM-2 compared to control transfectants. A
second aliquot of precipitated proteins was separated by
electrophoresis and stained with SyproRuby to detect co-
precipitated proteins. SyproRuby-stained gels showed a distinct
band of ,42 kDa, unique to the SK-N-ASpIRES.ICAM2 cells.
This band (#1, in upper panel of Fig. 1D) was confirmed to be
.99% identical to human actin by mass spectrometry, indicating
that in SK-N-ASpIRES.ICAM2 cells, actin associated with
ICAM-2. Co-immunoprecipitations were then done with antibod-
ies to a-actinin, actin, or ezrin, and precipitated products identified
by immunoblot. The immunoprecipitation/immunoblot per-
formed with a monoclonal antibody to a-actinin or control
immunoglobulin/polyclonal antiserum (Fig. 1E) showed that
control precipitations were appropriately negative and that equal
amounts of a-actinin were precipitated from SK-N-ASpIRESneo
and SK-N-ASpIRES.ICAM2 transfectants. Subsequent immuno-
blots to detect proteins that co-precipitated with a-actinin revealed
that both actin and ICAM-2 associated with a-actinin in lysates
from SK-N-ASpIRES.ICAM2 cells, but little or no actin or
ICAM-2 co-precipitated with a-actinin in lysates from SK-N-
ASpIRESneo cells (Fig. 1F). Data in Fig. 1F also suggested that
little actin associated with a-actinin in the absence of ICAM-2
expression. The specificity of the observed association of ICAM-2,
a-actinin, and actin was verified by immunoprecipitating ICAM-2
and immunoblotting for ICAM-2, a-actinin, or actin (Supporting
Information, Fig. S1). Ezrin was not detected to co-precipitate
with ICAM-2 or with actin in either cell line, nor was actin or
ICAM-2 detected to co-precipitate with ezrin (data not shown).
These co-immunoprecipitation data showed that ICAM-2
associated with a-actinin and actin in neuroblastoma cell lysates.
We note that the data are qualitative and do not necessarily reflect
the ratio in which these proteins associate. ICAM-2 is a heavily
glycosylated protein that exists in multiple forms that migrate as a
diffuse band having an area6density signal approximately 300%–
400% greater than that for the same amount of de-glycosylated
ICAM-2. Further, a-actinin induces actin self-association [32],
resulting in variable numbers of actin molecules associating with a
single a-actinin molecule. Nevertheless, the data indicate that
ICAM-2, a-actinin, and actin associate with each other in
neuroblastoma cell lysates.
ICAM-2-mediated redistribution of actin fibers is
disrupted by competitive peptides to inhibit ICAM-2/a-
actinin or a-actinin/actin binding, and is associated with
decreased tumor cell motility
The observed ICAM-2/a-actinin/actin association in cell
lysates suggested that ICAM-2 expression in neuroblastoma cells
might affect the function of the actin cytoskeleton. Alternatively, in
other types of transfected cells, ICAM-2 has been reported to
stimulate immune responses [22] and affect AKT phosphorylation
and chemosensitivity [25]. Therefore, we evaluated the effect of
ICAM-2 expression by SK-N-AS cells on AKT phosphorylation
and sensitivity to vincristine, doxorubicin, or etoposide, and on
actin fiber distribution and cell motility, using in vitro assays in
which immune stimulation was not a potential factor.
Effect of ICAM-2 expression on AKT phosphorylation,
drug sensitivity, and growth characteristics. In contrast to
published reports, we did not detect ICAM-2-mediated increases
in AKT phosphorylation as determined with a Ser473-specific
antibody on immunoblots, or in sensitivity to etoposide or
doxorubicin (data not shown). Neither did we detect ICAM-2
mediated-effects on cell cycle distribution, cell volume, or cell
doubling time (data not shown). ICAM-2 expression did affect the
morphology of cells as adherent monolayers. Adherent cells
expressing ICAM-2 appeared larger and less spheroid in shape
than cells expressing little or no ICAM-2 (evident in Fig. 2A).
Effect of ICAM-2 expression on actin fiber distribution and
cell motility. FITC-phalloidan staining showed that, ICAM-2
redistributed intracellular actin fibers from a transverse to a
juxtamembrane localization (Fig. 2A). This redistribution was
observed irrespective of cell density (data not shown). We reasoned
that if redistribution depended on the interaction of ICAM-2 with a-
actinin and actin, peptides designed to competitively inhibit these
interactions would be predicted to reverse the observed actin fiber
redistribution pattern in SK-N-ASpIRES.ICAM2 transfectants.
Consistent with this hypothesis, fibers reverted to a transverse
distribution in SK-N-ASpIRES.ICAM2 cells exposed to each
competitive peptide (Fig. 2B), but remained co-localized with cell
membranes in cells exposed to scrambled control peptides. Similar
results were also observed with NB-1691 neuroblastoma cells
transfected with pIRESneo or pIRES.ICAM2 (data not shown).
Co-incident with observed ICAM-2-mediated redistribution of
actin fibers was an inhibition of tumor cell motility (Figs. 2C and D),
as assessed with two types of in vitro assays: scratch (wound) assays
and modified Boyden chamber invasion assays. In scratch assays,
cell monolayers were overlaid with Matrigel immediately after
scratching, and the original scratch width was recorded in pixels.
Photomicrographs taken at 0 hours and 72 hours (Fig. 2C) showed
initial scratch widths of ,1125 pixels and ,1050 pixels for the
pIRESneo and pIRES.ICAM2 transfectants, respectively. At
72 hours pIRESneo transfectants had completed closed the scratch,
while the SK-N-ASpIRES.ICAM2 cells remained separated by a
width of ,450 pixels. In the second type of motility assay, a
modified Boyden chamber invasion assay,significantly fewer SK-N-
ASpIRES.ICAM2 cells migrated through a layer of Matrigel to the
distal side of porous membranes (P,0.0003, Fig. 2D), compared to
SK-N-ASpIRESneo cells. ICAM-2 expression also inhibited the
motility of NB-1691 cells transfected with pIRESneo and
pIRES.ICAM2 in this invasion assay (P,0.001, data not shown).
Inhibition of tumor cell motility by ICAM-2 has not been reported
previously. Most notably, in vitro results of phalloidan staining and
cell motility assays demonstrated a function for ICAM-2 indepen-
dent of its known immune stimulatory effect.
ICAM-2-mediated redistribution of actin fibers and
inhibition of tumor cell motility depended on an intact
intracellular domain
To then corroborate observations with competitive peptides
indicating that ICAM-2/a-actinin binding affected actin fiber
distribution, we transfected SK-N-AS cells to express a truncated
form of ICAM-2. ICAM-2 and ICAM-2DCD (ICAM-2 deleted
cytoplasmic domain) transfectants expressed similar levels of their
respective forms of ICAM-2 (Fig. 3A) and both forms of this
protein localized to cell membranes (Figs. 1C and S2), but
ICAM2DCD lacked the 26-amino acid intracellular domain to
which a-actinin binds. If ICAM-2/a-actinin binding were essential
to the observed ICAM-2-mediated redistribution of actin fibers,
expression of ICAM2DCD would have no effect on actin fiber
distribution and, similar to SK-N-ASpIRESneo cells, actin fibers
in SK-N-ASpIRES.ICAM2DCD cells would be in a transverse
configuration. Immunoprecipitation/immunoblot experiments us-
ICAM-2 Limits Metastasis
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(Fig. 3B) demonstrated that neither a-actinin nor actin associated
with ICAM-2 in control transfectants or in transfectants expressing
the truncated form of ICAM-2, and FITC-phalloidan staining
(Fig. 3C) confirmed that expression of the truncated form of
ICAM-2 lacking the a-actinin binding domain did not affect actin
fiber distribution. Consistent with these observations, SK-N-
pIRESneo and pIRES.ICAM2DCD transfectants migrated at
similar rates in scratch assays, closing initial scratch widths of
,525 pixels within 45 hours (Fig. 3D). The data show that
ICAM-2-mediated redistribution of actin fibers and inhibition of
tumor cell motility depended on an intact intracellular domain.
Figure 2. ICAM-2 expression affected the subcellular distribution of actin fibers and cell motility in two types of in vitro assays. A)
Confocal fluorescence microscopic images of actin fibers visualized by FITC-phalloidan (green) staining demonstrate that ICAM-2 expression
redistributed F-actin from a transverse to a juxtamembrane localization. Cell nuclei were visualized using DAPI (blue). B) Competitive peptides to
inhibit ICAM-2/a-actinin binding or a-actinin/actin binding reversed the ICAM-2-mediated juxtamembrane distribution of actin fibers in
neuroblastoma cells. C) In scratch assays, ICAM-2 transfectants migrated more slowly than control transfectants. The width of scratches at 0 hours
for pIRESneo and pIRES.ICAM2 transfectants were 1127 and 1044 pixels, respectively. At 72 hours, no gap remained in wells containing SK-N-
ASpIRESneo cells, while a scratch distance of ,450 pixel width remained in wells containing SK-N-ASpIRES.ICAM2 cells. D) In modified Boyden
chamber assays, ICAM-2 expression inhibited invasion of SK-N-AS cells through Matrigel to the distal side of porous membranes, as detected by Diff-
Quick (IMEB, Inc., San Marcos, CA), and quantitated using an Alpha Imager software, as detailed in Materials and Methods.
doi:10.1371/journal.pone.0003629.g002
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subcutaneous xenografts, but did inhibit development of
disseminated neuroblastoma tumors in a mouse model
of metastatic neuroblastoma
Because cell adhesion molecules and the actin cytoskeleton have
been reported to regulate tumorigenic potential, we injected SK-
N-ASpIRESneo and SK-N-ASpIRES.ICAM2 cells subcutaneous-
ly into SCID mice (5 mice per group, bilateral flank injections) and
observed the mice for tumor development. Both cell types
produced subcutaneous tumors within the same time frame
(Fig. 4A). Subcutaneous local tumor growth was rapid and mice
were euthanized for humane reasons before metastases were
observed. Since both ICAM-2 and control transfectants readily
formed subcutaneous tumors, we concluded that ICAM-2 was
unlikely to be acting as a tumor suppressor. However, data from in
vitro experiments showed that ICAM-2 expression was coincident
with actin fiber redistribution and inhibition of cell motility. Since
cell motility and the consequent migratory and invasive potential
are essential to the metastatic process, we used a preclinical model
of metastatic neuroblastoma to investigate whether ICAM-2
expression affected the development of disseminated tumors in
SCID mice. In this model of metastatic neuroblastoma there is no
primary tumor per se; but tumor cells injected intravenously must
migrate through the endothelial cell monolayer of vasculature and
invade stromal tissue to seed metastatic tumor foci and facilitate
tumor progression.
Mice injected intravenously with SK-N-ASpIRESneo cells (or
other neuroblastoma cell lines) develop tumors at multiple
anatomic locations and require euthanasia within 2–3 months
(Fig. 4B, left panels) due to progressive disease [33]. In contrast,
mice receiving SK-N-ASpIRES.ICAM2 cells intravenously devel-
oped no detectable tumors for .12 months and survived
significantly longer than mice receiving SK-N-ASpIRESneo cells
Figure 3. The effect of ICAM-2 on actin distribution and cell motility depends on an intact intracellular domain. A) SK-N-AS cells were
transfected to express a truncated form of ICAM-2 with a deleted cytoplasmic domain (ICAM2DCD). Expression of full length ICAM-2 and ICAM2DCD
was similar in respective transfected cell lines. B) ICAM-2, a-actinin, and actin co-precipitated only in transfectants expressing full length ICAM-2. C)
ICAM2DCD had no effect on actin fiber distribution. (Compare with Fig. 2A). D) ICAM2DCD did not affect migration of SK-N-AS cells in scratch assays.
Pixel width of scratches for pIRESneo and pIRES.ICAM2DCD transfectants at 0 hours and 27 hours were similar. No gap remained for either cell line
45 hours after scratch.
doi:10.1371/journal.pone.0003629.g003
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the ability of SK-N-AS cells to develop disseminated neuroblas-
toma tumors in SCID mice. In contrast to SK-N-ASpIRES.I-
CAM2 cells, SK-N-ASpIRES.ICAM2DCD cells produced dis-
seminated tumors (Fig. 3C) despite persistent expression of this
truncated protein (Fig. 3D). We concluded that ICAM-2-mediated
effects in this model depended on an intact intracellular domain.
Together, in vitro and in vivo data suggest that the observed
nonmetastatic phenotype could be due, at least in part, to the
interaction of membrane-bound ICAM-2 with the cytoskeletal
linker protein a-actinin.
To address the possibility that the observed results were a
consequence of artificial overexpression of ICAM-2, we used
RNAi techniques to decrease the expression of ICAM-2 protein
in SJNB-1A cells, the neuroblastoma cell line expressing the
highest endogenous level of ICAM-2 expression (Fig. 1A) and
investigated the phenotype of RNAi transfectants. At early
passages, stably transfected SJNB-1A cells expressed ,10% of
the level of ICAM-2, compared to control transfectants (Fig. 5A).
Consistent with previous results, control siRNA-transfected
SJNB-1A cells had a juxtamembrane distribution of actin fibers
(high ICAM-2::juxtamembrane actin fibers) (Fig. 5B) whereas
siRNA transfected SJNB-1A cells had transverse actin fibers (low
ICAM-2::transverse fibers). In addition, mice injected intrave-
nously with control transfected SJNB-1A cells (high ICAM-2)
developed no detectable tumors, while 40% of mice (N=10/
group) injected with ICAM-2 shRNA-transfected cells developed
multiple tumors (Fig. 5C). While we would have expected 100%
of the mice receiving ICAM-2 shRNA-transfected cells to
develop tumors, we note that even in the presence of selection
pressure in vitro, the suppression of ICAM-2 expression did not
persist long-term (Fig. 5A, passage 15), and results in Fig. 5C are
consistent with the transient downregulation of expression seen
for ICAM-2 in SK-N-AS ICAM-2 shRNA cells. These results
indicate that observations using neuroblastoma cells transfected
to increase expression of ICAM-2 are unlikely to be due to
artificial over-expression of this protein, since downregulation of
endogenous ICAM-2 in SJNB-1A cells produced the expected
phenotype: an inverse relationship between level of ICAM-2
expression with actin fiber redistribution and development of
disseminated tumors in vivo was seen in both cDNA and RNAi
transfected cell lines.
Figure 4. ICAM-2 expression inhibited the development of disseminated tumors but did not affect establishment or development
of local subcutaneous tumors. A) ICAM-2 did not affect the growth of neuroblastoma cells as subcutaneous tumors in SCID mice, a measure of
tumorigenic potential. B) ICAM-2 prevented the development of disseminated tumors, following intravenous tail vein injection of neuroblastoma
cells, a measure of metastatic potential. C) Mice injected intravenously with SK-N-ASpIRES.ICAM-2 cells survived significantly longer (P,0.001) than
mice receiving pIRESneo or pIRES.ICAM2DCD transfected cells. D) The failure of ICAM2DCD expression to suppress development of disseminated
tumors was not due to cessation of expression of the transfected cDNA, since expression of ICAM-2DCD protein persisted until time of death.
doi:10.1371/journal.pone.0003629.g004
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ICAM-2 expression and metastatic potential are inversely
related
We hypothesized that if the above observations reflected the
biology of primary tumors, ICAM-2 would be expressed by
primary neuroblastoma cells with limited potential for develop-
ment of progressive metastatic disease. This hypothesis was
investigated by immunostaining for ICAM-2 of a neuroblastoma
tissue microarray (TMA) obtained from the Children’s Oncology
Group. The TMA contained 90 independent patient samples, of
which 89 samples gave interpretable results.
Photomicrographs of representative tumor specimens demon-
strating the range of staining intensity of primary tumor samples
are shown in Fig. 6. The left panels of this Figure show
immunoperoxidase staining with a control rabbit polyclonal
antiserum and are appropriately negative. Of the right panels,
the top panel shows a weak (1+) but unequivocal level of ICAM-2
expression by 100% of normal lymphocytes infiltrating human
tonsilar tissue (Expression Score=100%61+=100). Lymphocytes
are one of the few types of normal cells that express ICAM-2
protein, and the photomicrograph reflects the known low-level
expression that has been reported for the few normal cells that do
express ICAM-2 [19].
The three lower right-hand panels demonstrate ICAM-2
staining in representative stage 4, stage 2, and stage 4S
neuroblastoma tumors. The stage 4 tumor is a high-risk, poorly
differentiated, Schwannian stroma-poor tumor comprised of
immature neoplastic cells. Patients with tumors of this stage and
histology have a poor prognosis with virtually certain development
of metastatic disease. Consistent with results obtained using
neuroblastoma cells lines, ICAM-2 expression (Expression
Score=0) and metastatic potential are inversely related. The
stage 2 tumor is a differentiating neuroblastoma, Schwannian
stroma-poor, comprised of some immature neoplastic cells (,10%
of tumor cells) as well as a sizeable population of neoplastic cells
that exhibit histologic features of ganglionic differentiation (,90%
of tumor cells). The immature neuroblastoma cells are negative for
ICAM-2, but all tumor cells exhibiting histologic features of
ganglionic differentiation express high levels (3+) of ICAM-2. The
overall score for this tumor specimen is 90%63+=270. The third
example is a stage 4S tumor, which represents a special subtype of
neuroblastoma with favorable prognosis [34]. It is defined as
Figure 5. RNAi techniques indicated that the observed ICAM-2-induced phenotype was unlikely to be due to artificial
overexpression of this protein. A) SJNB-1A cells express a relatively high endogenous level of ICAM-2 (Fig. 1A). The expression of ICAM-2 was
inhibited in a population of SJNB-1A cells transfected to stably express ICAM-2 shRNA. This inhibition was transient even in the presence of selection
pressure by G418 in vitro. B) Consistent with the proposed hypothesis, the high endogenous level of ICAM-2 expression in SJNB-1A cells is co-
incident with a juxtamembrane distribution of actin fibers (left panel); and when ICAM-2 expression is decreased, actin fibers are transverse (right
panel). C) Inhibition of ICAM-2 expression increased the development of disseminated neuroblastoma tumors in SCID mice injected intravenously
with SJNB-1A ICAM-2 shRNA cells.
doi:10.1371/journal.pone.0003629.g005
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limited tumor spread to the skin and/or liver that is amenable to
surgical resection. Despite its favorable prognosis, stage 4S
neuroblastoma is comprised of immature neuroblastoma cells that
are microscopically indistinguishable from immature cells seen in
high-risk neuroblastoma tumors.
The immature neuroblasts (100%) of this stage 4S tumor exhibit
strong (3+) ICAM-2 expression (Expression Score=100%63+
=300), again reflecting a correlation between relatively high level of
expression of ICAM-2 and low potential for progressive metastatic
disease. Notably, the contrast between results for ICAM-2 expression
of immature neuroblasts in the stage 4 tumor compared to the 4S
tumor indicates that ICAM-2 is not simply a differentiation marker.
Correlation between ICAM-2 expression and favorable
clinicopathologic features
While long-term survival data arenotyetavailable for the specific
patients whose tumors are included in the COG microarray, the
outcome for neuroblastoma patients canbe reasonably predictedon
the basis of well-characterized criteria that include histology,
Figure 6. Immunohistochemical analyses ICAM-2 expression with a tissue microarray containing primary tumor specimens from 90
individual patients showed that a relatively high level of ICAM-2 expression was associated with primary tumor cells recognized to
have limited metastatic potential. ICAM-2 antibody binding was detected using a peroxidase-tagged secondary antibody and DAB substrate
(brown), by standard methods. Specimens were counterstained with hematoxylin/eosin, to visualize morphology of tumor and stromal cells. Staining
was scored as: percent of stained cells6staining intensity (0, 1+,2 +,o r3 +). The scores for ICAM-2 expression of the Stage 4, Stage 2, and Stage 4S
tumor specimens pictured were 0, 270, and 300, respectively. Normal lymphocytes (a positive control) received a score of 100 (100% of
lymphocytes6a staining intensity of 1+). Each specimen is described in more detail in the text.
doi:10.1371/journal.pone.0003629.g006
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with favorable histology low risk tumors have a greater than 95%
overall survival with no adjuvant therapy beyond surgery. In
contrast, patients with unfavorable histology and MYCN-amplified
tumors have a ,20% 5-year survival despite intensive therapy.
Each tumorinthe TMAwasdesignated tohavea ‘‘good’’or‘‘poor’’
prognosis based on histopathology, age at diagnosis, MYCN copy
number status, and stage. The first three parameters were assessed
in line withthe criteriaadoptedby theInternationalNeuroblastoma
Pathology Committee, based on the Shimada classification [35].
With respect to histopathology, the most immature primary
neuroblastoma cells (neuroblasts) are characterized by small size
and scant cytoplasm. This undifferentiated cell type is usually
associated with high-risk disease and less favorable clinical outcome.
On the other extreme are cells with obvious advanced ganglionic
differentiation, with abundant cytoplasm that includes a prominent
basophilic golgi body area and a round eccentric nucleus with a
prominent nucleolus. Primary tumor cells exhibit varying degrees of
ganglionic differentiation. Cells with advanced ganglionic differen-
tiation are associated with lower-risk disease and favorable clinical
outcome. The presence of abundant stromal tissue (Schwannian
stroma), is also usually associated with a more favorable prognosis.
These criteria, in conjunction with age and tumor staging
information provided by the Children’s Oncology Group Biological
Studies Oversight Committee formed the basis of designation of
tumors in Table 1 as having ‘‘good’’ or ‘‘poor’’ prognosis.
A summary of the results for the staining of the 89 interpretable
specimens (Table 1) showed that 42% (37 of 89) of primary tumors
Table 1. Characteristics of tumors evaluated for ICAM-2 expression.
N ICAM-2 score ,30 ICAM-2 score $30 & #90* ICAM-2 score $160 & #300
52 13 24
Gender
Male 32 (62%) 9 (69%) 16 (67%)
Female 20 (38%) 4 (31%) 8 (33%)
Race
White 45 (87%) 9 (69%) 19 (79%)
Black 1 (2%) 1 (8%) 2 (8%)
Hispanic 2 (4%) 0 (0%) 0 (0%)
Filipino 1 (2%) 0 (0%) 0 (0%)
Unknown or other 3 (6%) 3 (23%) 3 (13%)
Age
,1 year 25 (48%) 4 (31%) 13 (54%)
$1y e a r-#18 months 3 (6%) 0 (0%) 0 (0%)
.18 months 24 (46%) 9 (69%) 11 (46%)
Stage
1 5 (10%) 3 (23%) 3 (13%)
2/2A/2B 9 (17%) 2 (15%) 3 (13%)
3 8 (15%) 3 (23%) 2 (8%)
4 18 (35%) 4 (31%) 9 (38%)
4S 9 (17%) 1 (8%) 6 (25%)
Stage not available 1 (2%) 0 (0%) 0 (0%)
N/A (GN patients) 2 (4%) 0 (0%) 1 (4%)
Shimada Pathology
Favorable Histology/GN 17 (33%) 5 (38%) 7 (29%)
Unfavorable Histology 19 (37%) 7 (54%) 10 (42%)
Post-Treatment 3 (6%) 0 (0%) 3 (13%)
Post-Treatment (UH by age) 1 (2%) 0 (0%) 0 (0%)
Unknown/missing 12 (23%) 1 (8%) 4 (17%)
Prognosis^
Good 19 (83%)
Poor 4 (17%)
ICAM-2 expressed by:
Differentiated ganglionic cells 4 (31%) 15 (63%)
Both differentiated cells and undifferentiated neuroblasts n/a 6 (46%) 6 (25%)
Neuroblasts 3 (23%) 3 (13%)
*No specimens received a score of .90 & ,160. ^ As defined in References 28, 34, and 35, and explained in the text.
doi:10.1371/journal.pone.0003629.t001
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ICAM-2 at relatively high levels (a score of .150 of a possible
300). Interestingly, all 89 samples scored either #90 or $160, with
no intermediate results. Consistent with the preclinical data from
neuroblastoma cell lines, ICAM-2 expression was associated with
favorable histologic features (exact 95% confidence interval,
62.6% to 95.3%) such as ganglionic differentiation or low-risk
stage [34,35]. Preclinical and TMA data support the hypothesis
that ICAM-2 is associated with a nonmetastatic phenotype in
primary neuroblastoma cells or cell lines.
Consistent with our hypothesis, we observed the highest levels of
ICAM-2 expression in neuroblastoma tumor cells associated with
the most favorable predicted clinical outcome. Namely, tumor
cells exhibiting histologic evidence of ganglionic differentiation
were the predominant subset of ICAM-2-positive cells.
Discussion
The novel findings of this study are that neuroblastoma cells
express ICAM-2 and that this expression is associated with
juxtamembrane distribution of actin fibers, decreased cell motility
in vitro, and suppressed development of disseminated tumors in a
preclinical model of metastatic neuroblastoma. These functions for
ICAM-2 were independent of immune stimulation, since the
tumorigenic potential of ICAM-2-expressing neuroblastoma cells
as xenografts in SCID mice was unaffected and cell phenotype was
altered in vitro as well as in vivo. Results with primary tumor
specimens also reflected the inverse relationship between ICAM-2
expression and predicted low-risk for progressive metastatic
disease, as was seen with the preclinical model.
Our data are in agreement with published literature in that the
novel function reported here for ICAM-2 is similar to that of the
related cell adhesion molecule CEACAM1 which binds directly to
actin to inhibit tumorigenesis [36], but without the requirement
for a cytoplasmic linker protein. ICAM-2 and CEACAM1 are also
similar in that their association with the actin cytoskeleton and
their suppression of tumor growth or metastasis (for CEAMCAM1
or ICAM-2, respectively) depend on an intact intracellular domain
[37 and data herein].
Multiple other functions have been reported for ICAM-2 in
different cell types. For example, gastric carcinoma tumor cells
transfected to express ICAM-2 induce an immune response
sufficient to produce a significant anti-tumor effect in immune
competent mice [22]. Potentially, the dual functions of stimulating
an immune response and inhibiting tumor cell motility could
contribute to a more favorable clinical outcome. ICAM-2 has also
been reported to increase the motility of endothelial cells and
leukocytes, and also to activate AKT leading to inhibition of
apoptosis [24–27]. Interestingly, ICAM-2 expression facilitated
rather than inhibited endothelial cell motility. The increase in
endothelial cell motility was directly related to an increased
phosphorylation of Rac, a small guanosine triphosphatase
(GTPase) and known regulator of actin organization, cell motility,
and angiogensis [27]. ICAM-2 also facilitated leukocyte migration,
albeit in a stimulus-specific manner [24]. Also in contrast to
published studies with osteosarcoma and breast cancer cells
[10,11], we detected no involvement of the linker protein ezrin in
the phenotype that ICAM-2 conferred on neuroblastoma cells.
The as yet unexplained differences in function of ICAM-2-
interacting proteins in different cell types are, nonetheless, relatively
common observations. Disease progression in uveal malignant
melanoma[38]isassociatedwitharelativelyhighlevelofexpression
of the ERM cytoskeletal linker protein ezrin. Conversely, disease
progression is associated with a relatively low level of expression of
this protein in serous ovarian carcinoma [39]. Similarly, the linker
protein a-actinin-4 decreases the tumorigenic potential of neuro-
blastoma cells [7] but is associated with a progressive phenotype in
breast and colorectal cancer [4,40].
We speculate that varying levels of expression of ICAM-2-
interacting proteins by specific cell types or the protein
composition of extracellular matrices or of adjacent cells in
different tissues may modulate the state of activation (conforma-
tion) and/or the function of ICAM-2. In tumor cells in particular,
constitutive activation of proteins up- or down-stream of the
bidirectional signals mediated by CAMs might also affect ICAM-2
function and cell phenotype. Quite likely, while some of the
protein interactions of ICAM-2 and the pathways or functions
affected by these interactions are known (e.g., binding of ICAM-2
to CD11a/CD18 and CD11b/CD18 integrins facilitates adhesion
of human leukocytes to endothelial cells [20]; and ICAM-2
induces phosphorylation of Rac and modulates motility of
endothelial cells [27]), others will undoubtedly be identified.
However, despite the multiple proteins and pathways known to
be affected by cell adhesion molecules in general and ICAM-2 in
particular, complete membrane-to actin linkages that regulate
CAM function in tumor cells have been difficult to identify.
Several laboratories, however, have described the involvement of
specific linker proteins and documented the impact of these linker
proteins on the migratory and metastatic potential of tumor cells.
In leukemic cells, for example, membrane-bound tetraspanin
proteins EWI-2 and EWI-F bind to cytoskeletal linker ezrin-
radixin-moesin (ERM) proteins to regulate cell migration [12].
This binding links cell membranes (EWI-1 and EWI-F proteins)
with cytoplasmic actin cytoskeletal proteins (ERM proteins), but
simultaneous association of these complexes with actin fibers has
not yet been reported. Also of note, individual linker proteins
appear to function differently in cells from different tumor types.
Inneuroblastomacells,wedetectedanassociationofICAM-2with
a-actinin, and data with competitive peptides and truncated proteins
suggest that this association plays a role in the regulation of the
observed ICAM-2-mediated phenotype. Potentially, in addition to
limiting the interaction of ICAM-2 with a-actinin, truncation of the
intracellular domain of ICAM-2 may also have prevented the
association of membrane-bound ICAM-2 with other as-yet-uniden-
tified intracellular proteins. However, the hypothesis that the novel
function for ICAM-2 described here depends at least partly on the
association of membrane-bound ICAM-2 with a-actinin and actin is
consistent with published reports documenting the role of a-actinin as
a determinant of metastatic potential [4,5,40,41] and the observation
that a-actinin associates with an unknown membrane protein to
decrease the tumorigenic or metastatic potential of neuroblastoma
cells [7]. Our data indicate that ICAM-2 may be such a membrane
protein. Our results are also consistent with the correlations between
the juxtamembrane localization of actin fibers and decreased motility
or decreased metastatic potential that have been reported for mouse
embryonic fibroblasts [42] and for primary oral squamous cell
carcinoma tumors [43], respectively.
Finally, the finding that ICAM-2 expression inhibited tumor cell
motility in scratch and modified Boyden chamber invasion assays
in vitro merits further discussion. With respect to metastasis, in vitro
cell motility assays may indicate how likely a tumor cell is 1) to
detach from a primary tumor (and enter systemic circulation); or 2)
to migrate through the vascular endothelial layer at an anatomic
site distant from the primary tumor; or, 3) once through the
endothelium, to invade the normal tissue stroma to facilitate
development of tumor at secondary sites.
We suggest that the component of the metastatic process most
likely affected by ICAM-2 is the invasion of normal stroma. This
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TMA, and from scratch and Boyden chamber assays. Firstly,
ICAM-2 was expressed predominantly by primary neuroblastoma
cells with some degree of ganglionic differentiation, and therefore
predicted low metastatic potential. The notable exception to this
was the 3+ staining of undifferentiated neuroblasts of some 4S
tumors. Patients with 4S tumors frequently have liver, dermal,
and/or limited (,10%) bone marrow, as well as adrenal,
involvement at diagnosis, i.e., secondary tumors are present at
diagnosis. However, unlike stage 4 tumors, 80% of patients with
4S disease do not develop progressive disease at metastatic sites.
Rather, 4S tumors usually regress spontaneously without treat-
ment, suggesting a limited invasive potential. Secondly, scratch
assays performed in the presence of Matrigel, in which
extracellular matrix proteins can influence cell function, showed
readily distinguishable differences between control and ICAM-2
transfectants. However, when these assays were performed in the
absence of Matrigel (data not shown), no differences in cell motility
were observed. Thirdly, results from standard Boyden chamber
invasion assays, in which cells invade a layer of Matrigel to migrate
toward a chemoattractant, corroborated results of scratch assays.
The presence of extracellular matrix proteins in vitro influenced
ICAM-2-mediated cell function. Fourthly, Stage 4 neuroblastomas
are progressively invasive tumors with a generally poor outcome;
while most Stage 4S tumors are self-limiting variants of
neuroblastoma despite transient involvement of skin, liver, or
bone marrow. The data are consistent with the hypothesis that
ICAM-2 limits the invasive potential of neuroblastoma cells.
We suggest further that the significance of ICAM-2 expression
can be compared with that of MYCN amplification. If MYCN is
amplified, it is regarded as a prognostic indicator for poor
outcome. If MYCN is not amplified, prognosis may still be poor—
normal MYCN copy number is uninformative [28]. Similarly,
ICAM-2 expression is associated with a more favorable prognosis.
However, lack of ICAM-2 expression is not necessarily associated
with poor prognosis; it is simply uninformative.
In summary, the observed ICAM-2/a-actinin/actin interaction
appears to represent a complete membrane-to-actin linkage that
contributes to regulation of the motility (possibly, the invasive
potential) and therefore the metastatic phenotype of neuroblasto-
ma cells. Our long-range goal is to determine the specific protein
domains essential to this regulation and to investigate the
possibility that small molecule agonists can be developed to mimic
the effects of ICAM-2 expression in neuroblastoma cells.
Materials and Methods
Immunoprecipitations and Immunoblots
Immunoprecipitations of ICAM-2, a-actinin, ezrin, and actin
done with antibodies IC2/2, MAB1682 (Chemicon International,
Temecula, CA), C-15 (Santa Cruz Biotechnologies), and 4968
(Cell Signaling Technology), respectively. Immunoblots for
ICAM-2, a-actinin, ezrin, actin, AKT, and phospho-AKT were
done with AF244 (R&D Systems, Minneapolis, MN) and C-20
(Santa Cruz Biotechnologies, Beverly, MA), CBL231 (Research
Diagnostics, Inc., Flanders, NJ), C-20 and C-15 (Santa Cruz
Biotechnologies), 4968, 9272, and 4051 (Cell Signaling Technol-
ogy), respectively. AKT and phospho-AKT standards were from
Cell Signaling Technology. Isotype-matched control antibodies
were from Jackson Immunolabs, Inc. (West Grove, PA).
Cell Motility Assays
Modified Boyden chamber invasion assays were done by
standard methods [44]. Briefly, cells were overlaid on ‘‘solidified’’
Matrigel (upper chamber), with a chemoattractant (lower
chamber) comprised of 10% fetal bovine serum in Dulbecco’s
Minimum Essential Medium supplemented with fibronectin
(20 mg/mL) Cells that migrated through (invaded) the Matrigel
layer and to the distal side of a membrane containing 8 micron
pores were recorded as photomicrographs using standard inverted
microscopy, and quantitated using an AlphaEase FC software
(Alpha Innotech, San Leandro, CA). Results were expressed as the
mean percentage of dark pixels/total pixels in 106 fields+S.D.
from a minimum of five fields per experiment, of six replicate
experiments.
‘‘Scratch’’ or ‘‘wound healing’’ assays were also done by
standard methods. In brief, cell were plated in chamber well slides
and cultured in Dulbecco’s Minimum Essential Medium supple-
mented with 10% fetal bovine serum until confluent. A 200
microliter pipet tip was used to ‘‘wound’’ the confluent
monolayers, which were immediately overlaid with 25% Matrigel.
As soon as the Matrigel solidifed, photomicrographs were taken
using an inverted microcroscope. Images were recorded at 0, 15,
24, and 48 hours after scratch.
Plasmids Containing ICAM-2 cDNA
The cDNA of ICAM-2 was isolated from human umbilical vein
cell RNA (Clonetics, San Diego, CA). Amplification was performed
at 95uC for 1 min, then 30 cycles of 94uC for 30 sec, 55uC for
30 sec, 72uC for 1 min, and 72uC for 7 min. Primers for full length
ICAM-2 were: forward (59GCTTCCGCTGCCTGGATTCT39)
and reverse (59AAGTCCAGGTGTTGTATTC39), and for trun-
cated ICAM-2: forward (59ACGCAGGATCCGCCAGA-
GATGTCCTCTTTCG) and reverse (TTGGATCCTGAT-
GAAGCAGAGCAGGACAGATG). cDNAs inserted into
pIRESneo2 (Clontech, San Jose, CA) were transfected with
FuGene6 (Roche Diagnostics, Indianapolis, IN), and transfectants
selected with G418. The St. Jude Hartwell Center for Bioinfor-
matics sequenced all plasmids.
RNAi-mediated decrease in endogenous ICAM-2
expression
The siRNA or shRNA sequence used to decrease expression of
endogenous ICAM-2 (CAAGAAGCTGGCGGTTGA) was de-
signed using Invivogen siRNA Wizard and Dharmacon siDesign
Center. siRNA sequences for transient transfections were synthe-
sized in the St. Jude Hartwell Center for Technology. shRNA for
stable transfections were done using psiRNA-hH1-ICAM2
(Invivogen). In this plasmid, shRNA expression is regulated by
the H1 promoter, and neomycin resistance gene is regulated by
expression of the SV40 promoter. Transfections were done with
FuGene6 (Roche Applied Science, Indianapolis, IN). Stably
transfected cells were selected using G418, and the entire
population of G418-resistant cells was used for in vivo experiments.
Control transfections were done with transfection reagent only or
with scrambled RNAi and transfection reagent. Specificity of
RNAi was assessed by probing immunoblots of RNAi and control
transfectants for a minimum of three additional, irrelevant
proteins.
Competitive peptides that inhibit ICAM-2/a-actinin or a-
actinin/actin binding
Peptides comprised of amino acids that mediate binding of
ICAM-2 to a-actinin or of a-actinin to actin, or scrambled control
peptides were linked to the antennapedia 16-mer that facilitates
intracellular peptide accumulation. The antennapedia 16-mer
(RQIKIWFQNRRMKWKK [45] was coupled to the 59-end of
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acids 241-248 to inhibit ICAM-2/a-actinin binding [30]);
LARRRWAV (scrambled control); MTLGMIWTIILRFA (a-
actinin amino acids 122–135 to inhibit a-actinin/actin binding
[46]); WIRMIAFGLIMTLT (scrambled control). Oligopeptides
were synthesized in the St. Jude Hartwell Center for Bioinfor-
matics and were .99% pure. SK-N-ASpIRES.ICAM2 cells were
incubated with 12.5 mM peptide for 4 hours, at which time cells
were fixed with paraformaldehyde and the subcellular localization
of actin fibers evaluated using FITC-conjugated phalloidan by
standard methods.
Distribution of F-actin
Standard methods were used to fix cells using paraformaldehyde
and incubate them for 30 minutes at room temperature with
10 mg fluorescein isothiocyanate (FITC)-conjugated phalloidan/
mL phosphate buffered saline. Actin fibers were visualized by
confocal fluorescence microscopy, also by standard methods.
Mouse Models of Neuroblastoma
Subcutaneous xenografts: 1610
7 neuroblastoma cells transduced
to express luciferin were injected subcutaneously in each hind flank
of SCID mice (5 mice/group), and imaged noninvasively by
standard methods. Disseminated neuroblastoma: 5610
5 neuroblas-
toma cells injected intravenously into the tail veins of SCID mice
produced disseminated tumors in 100% of mice [33]. In this model,
there is no ‘‘primarytumor’’, buttumordevelopment mimicsthat of
clinical metastaticneuroblastoma inthat tumorsdevelop in multiple
anatomiclocationsincludingsupra-renal andbonemarrow.Animal
protocols were in accordance with the guidelines of the St. Jude
Animal Care and Use Committee.
Immunostaining primary tumor samples for ICAM-2
The neuroblastoma tissue microarray obtained from the Chil-
dren’s Oncology Group Neuroblastoma Biology Committee, Chil-
dren’s Hospital of Philadelphia included triplicate cores from 90
distinct patients at presentation: 47 low-risk group (16 Stage 1, 16
Stage 2, 15 Stage 4S); 43 high-riskgroup (15 Stage 3, 28 Stage 4) [28].
Sections were incubated overnight with polyclonal antiserum to
ICAM-2 (ProteinTech Group, Inc., Chicago, IL), and antibody
binding detected with biotinylated secondary antibody and ABC
Reagent (Vectastain ABC Kit, Vector Laboratories, Burlingame,
CA). The primary antibody was not detected to cross react with
any other protein, including ICAM-1. Results were scored blinded
by JDK, according to the following criteria: staining intensity: 1,
weak; 2, moderate; or 3, strong. The percentage of tumor cells
positive for ICAM-2 was estimated by counting at least 500 tumor
cells in each core. Scores=% positive cells6estimated intensity.
The core with the highest score determined the final value for each
tumor. A score #20 was considered negative.
Statistical Analyses
With the exception of the tissue microarray, data were analyzed
with GraphPad Prism software (San Diego, CA). Results for cell
motility assays were expressed as the number of pixels occupied by
Diff-Quick (IMEB Inc., San Marcos, CA)-stained cells on the
distal side of membranes with 8 mm pores. Data were analyzed
using a two-sided t-test. Migration assays were done at least three
times, with six replicates of each cell line. Kaplan-Meier plots
compared survival using a log-rank (Mantel-Haenszel) test.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0003629.s001 (1.11 MB TIF)
Figure S2
Found at: doi:10.1371/journal.pone.0003629.s002 (1.27 MB TIF)
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